ReviewF1000prime reports2015
Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop.
Review in F1000prime reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- PGE2 displays immunosuppressive effects during human active tuberculosis.Scientific reports · 2021Trial
- Abnormalities of lipid metabolism in the progression and treatment of depression.Frontiers in psychiatry · 2025Review
- Macrophage: A Cell With Many Faces and Functions in Tuberculosis.Frontiers in immunology · 2022Review
- Insights into the molecular determinants involved inVirulence · 2021Review
- Association between serum PGEAnnals of medicine and surgery (2012) · 2021Article
- Novel Role for Macrophage Galactose-Type Lectin-1 to Regulate Innate Immunity againstJournal of immunology (Baltimore, Md. : 1950) · 2021Article
- The Manipulation of the Lipid Mediator Metabolism as Adjunct Host-Directed Therapy in Tuberculosis.Frontiers in immunology · 2021Review
- PE_PGRS31-S100A9 Interaction Promotes Mycobacterial Survival in Macrophages Through the Regulation of NF-κB-TNF-α Signaling and Arachidonic Acid Metabolism.Frontiers in microbiology · 2020Article
- Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity inFrontiers in immunology · 2020Article
- Macrophage nuclear receptors: Emerging key players in infectious diseases.PLoS pathogens · 2019Review
- Infection resisters: targets of new research for uncovering natural protective immunity againstF1000Research · 2019Review
- Advances in Cardiovascular Disease Lipid Research Can Provide Novel Insights Into Mycobacterial Pathogenesis.Frontiers in cellular and infection microbiology · 2019Review
- Regulation of Three Virulence Strategies of Mycobacterium tuberculosis: A Success Story.International journal of molecular sciences · 2018Review
- The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy.Frontiers in microbiology · 2018Review
- The transcriptome of Mycobacterium tuberculosis in a lipid-rich dormancy model through RNAseq analysis.Scientific reports · 2017Article
- Lipoxin A4, a 5-lipoxygenase pathway metabolite, modulates immune response during acute respiratory tularemia.Journal of leukocyte biology · 2017Article
- Unbiased Identification of Blood-based Biomarkers for Pulmonary Tuberculosis by Modeling and Mining Molecular Interaction Networks.EBioMedicine · 2017Article
- Early Production of the Neutrophil-Derived Lipid Mediators LTBBioMed research international · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid mediators play an important role in infection- and tissue injury-driven inflammatory responses and in the subsequent inhibition and resolution of the response. Here, we discuss recent findings that substantiate how Mycobacterium tuberculosis promotes its survival in the host by dysregulation of lipid mediator balance. By inhibiting prostaglandin E2 (PGE2) and enhancing lipoxin production, M. tuberculosis induces necrotic death of the macrophage, an environment that favors its growth. These new findings provide opportunities for developing and repurposing therapeutics to modulate lipid mediator balance and enhance M. tuberculosis growth restriction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.